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CASE REPORT
A 59-year-old man was admitted with numbness, pain, and a tingling sensation in both lower legs. He was
initially diagnosed with diabetic peripheral neuropathy based on a symptom questionnaire and a quantitative
sensory test. Despite symptomatic treatment of diabetic neuropathy, he complained of worsening sensory
symptoms and additional motor weakness in both lower extremities. As the motor weakness of both extremities
became more aggravated over time, brain and spine imaging tests and a nerve conduction test were performed.
The nerve conduction study revealed motor and sensory axonal neuropathy. In his cerebrospinal analysis,
albumino-cytologic dissociation, which is compatible to the Gillian-Barre syndrome, was found. Cerebrospinal fluid
analysis showed albumino-cytologic dissociation. He was treated with intravenous immunoglobulin and his
neurologic deficits were gradually improved. (Korean J Intern Med 2010;25:217-220)
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INTRODUCTION
Neuropathy in diabetic patients is heterogenous, so
can present with many sensory and motor symptom [1].
Diverse neuropathic symptoms are important in the early
recognition and diagnosis of diabetic neuropathy (DN).
If the neurological symptoms are atypical and are not
resolved, especially when motor neurons were involved,
other causes should be considered because DN is an
exclusive diagnosis and nondiabetic neuropathy may be
present in diabetic patients [2]. Among these, Guillain-
Barre syndrome (GBS) is a disease that should be considered
when acute flaccid weakness occurs [3]. 
We report here a case of diabetic neuropathy combined
with GBS, which was diagnosed with some delay due to
the underlying diabetes.
CASE REPORT
A 59-year-old man complained of pain and numbness
in both lower legs of several months duration. His medical
history was diabetes of 15 years and he recently had
caught a common cold. He had no significant neurological
history and received insulin treatment for glucose control.
Laboratory findings showed: proteinuria (+), glucosuria
(++), hemoglobin 10.1 g/dL,  aspartate aminotransferase
(AST)/alanine aminotransferase (ALT) 24/30 IU/L,
creatinine kinase (CK) 64 U/L, glucose 288 mg/dL, Na+/
K+/Cl- 130/4.1/98 mmol/L, blood urae nitrogen (BUN)/
creatinine (Cr) 28/1.2 mg/dL, HbA1c 8.8%, C-peptide 1.2
ng/mL, and total cholesterol 248 mg/dL. On the
neurological examination, there were no abnormal
findings for the motor response. After admission, the
patient was treated with insulin for glucose control and
alpha-lipoic acid (ALA), gabapentin, and amytryptilin for218 The Korean Journal of Internal Medicine Vol. 25, No. 2, June 2010
diabetic peripheral neuropathy based on symptoms (total
symptom score, 9.65), 10 g monofilament test, and
quantitative sensory test (Table 1). After two days,
however, the sensory symptoms in both legs were more
aggravated and there was additional motor weakness in
the lower legs. These symptoms were not present before
admission. On day 4, he could not walk and had difficulty
sensing movement of upper extremities, although he had
not had any discomfort in ambulation at the visiting
hospital. Cervical and brain MRI were performed but
resulted in near normal findings except for mild herniation
of an intervertebral disc. On day 5, aggravated weakness
of the lower legs had spread to the upper extremities,
so we consulted with the neurology department. Deep
tendon reflex was absent and so cerebrospinal fluid (CSF)
examination and a neurophysiological study were per-
formed. The CSF showed albumino-cytologic dissociation
(Table 2) and the electrodiagnostic finding was acute
motor and sensory axonal neuropathy compatible with
GBS (Table 3). Immunoglobulin was the administered
intravenously and the neurological deficit of motor
weakness improved gradually over the next week, allowing
the patient to be discharged. The sensory discomforts
however, such as pain, numbness, and tingling sense,
which were thought to be caused by DN, were little relieved
with continuous medication of ALA and gabapentin.   
DISCUSSION
Many diabetic patients suffer from neuropathic
symptoms involving sensory and motor nerves [1,4].
However, motor neuron involvement including paralysis
or weakness of extremities is not common in DN. Generally
confirmation of DN can be established by neuropathic
symptoms, sensory and autonomic function test, and
quantitative electrophysiology. Nevertheless, other
Table 2. Cerebrospinal fluid finding of the patient
White blood cell, /mm3 9
Neutrophile, % 0
Lymphocyte, % 0
Red blood cell, /mm3 1
Protein, mg/dL 127.0
Glucose, mg/dL 75
Table 1. Quantitative sensory test results on admission day
Sensory test Right Left
Hand Foot Hand Foot
Cold sense (32 - 28˚C) 25.7˚C Absent 24.9˚C Absent
Warm sense (32 - 36˚C) 38.9˚C Absent 39.0˚C Absent
Cold pain (20 - 5˚C) 3.5˚C Absent 4.1˚C Absent
Heat pain (40 - 45˚C) 49.0˚C Absent 48.1˚C Absent
Vibration threshold Abnormal Abnormal Abnormal Abnormal
Table 3. Nerve conduction studies
Motor nerves (Right / Left) TL, ms A, mV NCV, m/sec F-wave, ms
Median 9.2 / 8.9 7.552 / 11.84 40.0 / 42.0 Absent
Ulnar 10.7 / 10.8 8.269 / 1.506 52.0 / 52.0 Absent
Tibial 18.8 / 18.9 0.891 / 0.704 29.0 / 28.0 52.5
Peroneal Absent / 22.0 Absent / 0.090 Absent / 34.0 Absent
Sensory nerves (Right / Left) TL, ms A, µV NCV, m/sec
Median 7.8 / 7.0 5.095 / 9.791 48.0 / 55.0
Ulnar Absent / Absent Absent / Absent Absent / Absent
Radial Absent / Absent Absent / Absent Absent / Absent
Superficial peroneal Absent / Absent Absent / Absent Absent / Absent
Sural Absent / Absent Absent / Absent Absent / Absent
TL, terminal latency; A, amplitude; NCV, nerve conduction velocity.causes should be excluded [2]. Cerebrovascular accident,
peripheral vascular insufficiency, spinal disease, periodic
paralysis, myasthenia, transverse myelitis, toxic neuropathy,
diabetic peripheral neuropathy, and GBS are all possible
causes [5,6]. 
Since the prognosis of the neuropathic patient sometimes
is dependent on early recognition and prompt treatment
of the cause, an exact diagnosis is needed in the early
period of the disease. To avoid misdiagnosis when the
patient suffers from neuropathic symptoms combined
with acute weakness or paralysis of limbs, the physician
must be aware of the possibility of GBS, even if the patient
is being treated for another disease. Although there are no
reports show of a high risk of GBS in diabetic patients, a
few cases of GBS associated with diabetic ketoacidosis
have been described [7]. GBS underlying DN is uncommon
but could possibly be a serious cause of paralysis or weakness
of limbs, although this condition can be overlooked on
presentation. Prompt and sufficient evaluation and
management should be done in the early stages when
patients are suffering from neuropathic symptoms which
are not explained by previously diagnosed underlying
disease. 
GBS is a treatable disease which is associated with
morbidity and mortality if untreated [8]. GBS is the
commonest peripheral neuropathy affecting children
but it can occur at any age and condition. It is characterized
by rapidly progressing symmetric limb weakness, loss of
tendon reflexes and sensory signs, and autonomic
dysfunction [9]. Diverse symptoms in GBS can occur
according to the subtypes. Acute peripheral neuropathy
in GBS includes acute inflammatory demyelinating
polyradiculoneuropathy, acute motor axonal neuropathy,
and acute motor and sensory axonal neuropathy [10]. The
onset of neurological symptoms, such as flaccid weakness
of lower limbs, is usually sudden, but is possible anytime
between 1 to 28 days after the prodromal event. Weakness
of the limbs is usually present bilaterally with symmetrical
involvement spreading upwards to the arms, but asym-
metrical presentation and only distal involvement of the
legs are also possible [3]. Although the exact pathogenic
mechanisms are uncertain, there is considerable evidence
that an acute demyelinating process occurs by an immune-
mediated reaction with neural antigen after various viral
illnesses including herpes, mumps, mycoplasma,
cytomegalovirus and Campylobacter or after immunization
[3,11].
For the diagnosis of GBS, CSF findings of increased
protein and normal cell count is helpful. In addition,
neurophysiological examinations including nerve
conduction studies are essential for the confirmation of
GBS. Marked slowing of motor conduction velocity,
prolonged distal latency, and conduction block can be
shown in nerve conduction studies. Early symptomatic
and supportive treatments including careful monitoring of
vital signs are the mainstay of the management. Until now
plasma exchange or intravenous immunoglobulin have
been recommended for effective treatment [12]. Several
factors such as occurrence in adulthood, rapid development
of paralysis, delay in the diagnosis, marked distal
involvement, a low amplitude or fibrillation pattern in
the electromyographic potential have been suggested as
predictors of poor prognosis [3].
In our case, due to diagnostic delay, rapid progression
and electromyografic findings, a poor prognosis was
predicted. However, near complete recovery was achieved.
We report a case of DN combined with overlooked GBS
that was detected with delay to encourage prudence in
caring for neuropathic diabetic patients. 
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